The comparative clinical effects of valsartan and ramipril in patients with heart failure

Korean Circulation Journal

Volumn 38, Issue 2, 2008, Pages 101-109

  Ki, Hong Lee ^a   Myung, Ho Jeong ^a   Young, Keun Ahn ^a   Woo, Seok Lee ^a   Dae, Ho Jung ^a   Jeong, Gwan Cho ^a   Jong, Chun Park ^a   Jung, Chaee Kang ^a   Seok, Kyu Oh ^b   Nam, Ho Kim ^b   Kyung, Ho Yun ^b   Nam, Jin Yoo ^c   Moon, Yong ^d   Jay, Young Rhew ^d   Ji, Hyun Lim ^d   Seong, Hee Jeon ^d   Ok, Young Park ^e   Seung, Uk Lee ^f   Dong, Goo Kang ^f  

^a Chonnam National University Medical School   (South Korea)

^b Wonkwang University School of Medicine   (South Korea)

^c Gunsan Medical Center   (South Korea)

^d Presbyterian Medical Center   (South Korea)

^e Seonam University   (South Korea)

^f Gwangju Christian Hospital   (South Korea)

Author keywords

Angiotensin; Heart failure; Ventricular remodeling

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; RAMIPRIL; VALSARTAN;

ADULT; ARTICLE; CHEMICAL ANALYSIS; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; COUGHING; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; HEALTH CENTER; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; RATING SCALE; STATISTICAL SIGNIFICANCE; SYMPTOM; SYSTOLE; THERAPY EFFECT; UNIVERSITY HOSPITAL; UNSPECIFIED SIDE EFFECT; VITAL SIGN;

EID: 41349100494     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2008.38.2.101     Document Type: Article

References (30)

1. Ryu WS, Kim SW, Kim CJ. Overview of the renin-angiotensin system. Korean Circ J 2007;37:91-6.
2. Pfeffer MA, Braundwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement (SAVE) trial. N Engl J Med 1992;327:669-77.
3. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet 1997;349:747-52.
4. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
5. Yusuf S, Ostergren JB, Gerstein HC, et al. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005;112:48-53.
6. Urata H, Boehm KD, Philip A, et al. Cellular localization and regional distribution of an angiotensin II forming chymase in the heart. J Clin Invest 1993;91:1269-81.
7. Morice AH, Lowry R, Brouwn MJ, Higinbotam T. Angiotensin- converting enzyme and the cough reflex. Lancet 1987;2:1116-8.
8. Minisi AJ, Thames MD. Distribution of left ventricular sympathetic afferent demonstrated by reflex responses to transmural myocardial ischemia and to intracoronary and epicardial bradykinin. Circulation 1993;87:240-6.
9. Critchley JAJH, Gilchrist N, Ikeda L, et al. A randomized, double-masked comparison of the antihypertensive efficacy and safety of combination therapy with losartan and hydrochlorothiazide versus captopril and hydrochlorothiazide in elderly and younger patients. Curr Ther Res 1996;57:392-407.
10. Anderson GH Jr, Streeten DH, Dalakos TG. Pressure response to 1-sar-8-ala-angiotensin II (saralasin) in hypertensive subjects. Circ Res 1977;40:243-50.
11. Kang PM, Landau AJ, Eberhardt RT, Frishman WH. Angiotensin II receptor antagonists: a new approach to blockade of the rennin-angiotensin system. Am Heart J 1994;127:1388-401.
12. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.
13. Bristow MR. Why does the myocardium fail?: insights from basic science. Lancet 1998;352 (Suppl I):SI8-14.
14. Swan HJ. Left ventricular systolic and diastolic dysfunction in the acute phases of myocardial ischaemia and infarction and in the later phases of recovery: function follows morphology. Eur Heart J 1993;14:48-56.
15. Mitchell GF, Pfeffer MA. The role of geometry in left ventricular remodeling after myocardial infarction. Cardiol Rev 1995;3:71-8.
16. Taylor GJ, Humphries JO, Mellits ED, et al. Predictors of clinical course, coronary anatomy and left ventricular function after recovery from acute myocardial infarction. Circulation 1980;62:960-70.
17. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76:44-51.
18. Kim KH, Jeong MH, Park JC, et al. The comparison among low and high doses of imidapril, and combined imidapril with losartan in patients with ischemic heart failure after coronary intervention. Korean Circ J 2000;30:965-72.
19. Rhew JY, Jeong MH, Lee KY, et al. The clinical effects of a combined agent including losartan and hydrochlorthiazide, Hyzaar®, in patients with ischemic heart failure. Korean Circ J 2002;32:349-54.
20. Park HY, Jeong MH, Lee SH, et al. The effects of cilazapril on left ventricular remodeling after coronary intervention in patients with ischemic heart failure. Korean Circ J 1998;28:1964-72.
21. Lim SC, Rhee JA, Jeong MH, et al. Predictive factors for the recovery of left ventricular dysfunction in patients with acute myocardial infarction. Korean Circ J 2007;37:113-8.
22. de Denus S, Pharand C, Williamson DR. Brain natriuretic peptide in the management of heart failure: the versatile neurohormone. Chest 2004;125:652-68.
23. Groenning BA, Nilsson JC, Sondergaard L, Kjaer A, Larsson HB, Hildebrandt PR. Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations. Eur J Heart Fail 2001;3:699-708.
24. Yan RT, White M, Yan AT, et al. Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both. Am J Cardiol 2005;96:698-704.
25. Talwar S, Squire IB, Downie PF, et al. Profile of plasma N-terminal proBNP following acute myocardial infarction: correlation with left ventricular systolic dysfunction. Eur Heart J 2000;21:1514-21.
26. Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens 2004;22:2253-61.
27. Lindholm LH, Ibsen H, Borch-Johnsen K, et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002;20:1879-86.
28. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine. Lancet 2004;363:2022-31.
29. Ogihara T, Asano T, Ando K, et al. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 2002;40:872-9.
30. Kasama S, Toyama T, Hatori T, et al. Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure. Heart 2006;92:625-30.